Endocrine Abstracts

2-Methoxyoestrogens are emerging as a new class of anti-neoplastic agents. 2-Methoxyoestradiol (2-MeOE2), an endogenous oestrogen metabolite, has shown anti-proliferative effects in ER+ve and ER-ve breast cancer cell lines. In this study we have investigated the effects of sulphamoylated derivatives of 2-MeOE2, 2-methoxyoestradiol-3-O-monosulphamate (2-MeOE2MATE) and 2-methoxyoestradiol 3,17 bis sulphamate (2-MeOE2bisMATE) in ER-ve MDA-MB-231 cells. Both 2-MeOE2MATE and 2-MeOE...

The Na+/I- symporter (NIS) is a plasma membrane glycoprotein that mediates active I- transport in the thyroid follicular cells (the first step in thyroid hormone biosynthesis), and in other tissues, such as lactating mammary gland. NIS is the basis for the effective use of radioiodide in the diagnostic and treatment of thyroid cancer. NIS mutations hae been identified as causes of congenital iodide transport defect (ITD). We have isolated the cDNA that encodes NIS, generated h...

2-Methoxyoestradiol (2-MeOE2) is a human endogenous metabolite of oestradiol which is known to inhibit the proliferation of breast cancer cells. Sulphamoylation of 2-MeOE2 greatly enhances its ability to inhibit breast cancer cell proliferation and induce apoptosis. To establish whether 2-MeOE2 and its mono- and bis-sulphamoylated derivatives would also be an effective treatment for other endocrine cancers, we have investigated their effects, and those of 2-ethyloestradiol (2-...

Ovarian cancer is the leading cause of death from all gynaecological malignancies. The observation that decreased levels of the natural oestrogen-17beta metabolite, 2-methoxyoestradiol (2-MeOE2) may create a predisposition to oestrogen dependent cancer, has led to considerable interest in the potential use of oestrogen derivatives for the prevention and treatment of hormone dependent cancers. The sulphamoylated oestrone derivative 2-methoxyoestrone-3-O-sulphamate (2-MeO...

This is the first prospective study to compare the efficacy and safety of medical therapy and surgery as primary therapy in acromegaly.A total of 104 patients with untreated acromegaly were enrolled. Eighty-one patients randomized to receive either octreotide LAR 20 mg (n=40) or surgery (n=41) completed the 48 weeks treatment period, and constituted the population used for this analysis, regardless of response to treatment.<p class="abs...